[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cellulitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cellulitis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,51,81,113,142],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100644116","phase-3-naproxen-versus-placebo-as-adjunct-treatment-of-cellulitis-a-randomized-controlled-trial-100644116",false,"NCT07665476","Naproxen Versus Placebo as Adjunct Treatment of Cellulitis: A Randomized Controlled Trial","NVP","Inclusion Criteria:\n\n* adults (age ≥18 years) diagnosed with cellulitis and determined by the treating physician to be eligible for outpatient treatment with oral cephalexin.\n\nExclusion Criteria:\n\n* These are appropriate exclusions according to eligibility for treatment with naproxen in clinical practice, and we believe that relatively few patients will be excluded. We will exclude participants for any of the following reasons: (a) Age \\\u003C18 years; (b) Patient already taking oral antibiotics or NSAIDs; (c) Treating physician decides IV antibiotics are required; (d) Skin abscess requiring incision and drainage; (e) Known prior skin or soft tissue infection secondary to methicillin-resistant Staphylococcus aureus (MRSA); (f) Cellulitis secondary to a human or animal bite; (g) Penetrating wound or water exposure resulting in cellulitis; (h) Surgical site infection; (i) Pregnancy or breastfeeding; (j) Prior gastric bypass surgery; (k) Patients on dual antiplatelet therapy; (l) Patients on warfarin, low molecular weight heparin, or direct oral anticoagulant therapy; (m) Severe uncontrolled heart failure, or coronary artery bypass grafting (CABG) surgery within 14 days prior to the index visit, or planned CABG surgery within 21 days following the index visit.; (n) History of gastric\u002Fduodenal ulcer or gastrointestinal bleeding in the past 12 months; (o) Known kidney impairment with an estimated glomerular filtration rate \\\u003C30 mL\u002Fmin documented on the electronic health record at any time within the past three months; (p) Known hyperkalemia documented on the electronic health record at any time within the past three months; (q) Liver cirrhosis; (r) Inflammatory bowel disease; (s) History of asthma, urticaria or allergic reactions after taking NSAIDs or aspirin; (t) Allergy to cephalosporins or history of anaphylaxis to penicillin; (u) Inability to provide informed consent.\n\nExclusion criteria (i) through (s) are known contraindications to NSAIDs.","ALL","18 Years",{"count":19,"type":20},884,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","Cellulitis is a painful bacterial skin infection commonly seen in Canadian emergency departments. Cellulitis has a negative impact on patients' quality of life and productivity. While this is a bacterial infection, there is evidence inflammation also contributes to the disabling symptoms of pain, redness and swelling. Some studies have suggested that a nonsteroidal anti-inflammatory drug (NSAID) such as naproxen in addition to antibiotics may control inflammation and speed recovery. However, these studies have had too few patients to tell if there is a true benefit.\n\nThe investigators are proposing a randomized controlled trial of patients with cellulitis to compare oral naproxen (500 mg twice daily) plus oral antibiotics versus placebo plus oral antibiotics. The investigators will compare the proportion of patients who have an early clinical response (reduction in area of redness ≥20% at 72 hours), cure, treatment failure, adverse events, and hospital admission.\n\nIf naproxen proves to be superior to placebo, this simple, low-cost intervention will speed time to recovery with less pain for patients, and may potentially reduce treatment failure and time missed from activities. The results of this trial will help inform future cellulitis treatment guidelines.",[26,27,28,29],"Cellulitis","Skin Disease, Infectious","Infection","Skin and Soft Tissue Infections (SSTIs)",[31,32,26,33,34,35,36,37],"Infectious Diseases","Emergency Medicine","naproxen","antibiotics","oral antibiotics","cephalexin","anti-inflammatories","NOT_YET_RECRUITING","2026-06-18",{"date":41,"type":42},"2026-06-24","ACTUAL",{"date":44,"type":20},"2026-09-01",{"date":46,"type":20},"2031-12-01",{"name":48,"class":49},"Ottawa Hospital Research Institute","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":50},"100630773","validation-of-the-use-of-the-arteriovenous-tension-difference-in-co2-under-hyperbaric-conditions-100630773","NCT07492030","Validation of the Use of the Arteriovenous Tension Difference in CO2 Under Hyperbaric Conditions","Use of Central Venous-arterial Carbon Dioxide Tension Difference to Diagnose Low Cardiac Output in Patients With Septic Shock Undergoing Hyperbaric Oxygen Therapy","SEPTICO2HBO","Inclusion Criteria:\n\n* Diagnosis of necrotizing fasciitis complicated by septic shock as defined by the Surviving Sepsis Campaign\n* Indication for HBOT according to the criteria of the 2016 European Consensus Conference\n* Patient intubated and ventilated prior to the HBOT session, receiving intravenous sedation at doses sufficient to be in a passive ventilation state\n* Patient equipped with a central venous line in the superior vena cava allowing central venous blood gas analysis\n* Patient with an arterial catheter allowing arterial blood gas analysis\n\nExclusion Criteria:\n\n* \\- Minors\n* Pregnant women\n* Persons deprived of their liberty (prisoners, persons under guardianship or trusteeship)\n* Persons not affiliated with or not covered by a social security system\n* Patients on spontaneous ventilation\n* Patients without an echocardiographic assessment window (anechoic)\n* Severe ARDS according to the Berlin classification\n* Technical impossibility of sampling central arterial or venous blood\n* Absolute contraindication to hyperbaric oxygen therapy (undrained pneumothorax, unstable angina or acute myocardial infarction, severe asthma attack)\n* Relative contraindication to hyperbaric oxygen therapy\n\n  * Respiratory: Chronic respiratory failure, severe pulmonary emphysema\n  * Circulatory: Rhythm or conduction disorders\n  * Neurological: uncontrolled epilepsy\n  * ENT: sinusitis, otitis, chronic rhinitis; laryngocele; acute otitis media; osteospongiosis\n  * Ophthalmic: retinal detachment",{"count":60,"type":20},74,"OBSERVATIONAL","The central venous-arterial carbon dioxide tension difference is used daily in intensive care to establish peripheral tissue hypoperfusion, mainly mediated by a low cardiac index.\n\nThe partial pressures of gases (oxygen, carbon dioxide) increase in the blood of patients breathing 100% oxygen in hyperbaric conditions.\n\nThus, the validity of this biomarker in situations of acute circulatory failure during a hyperbaric oxygen therapy session has not been established.\n\nThe objective of the study is therefore to establish the diagnostic performance of the central venous-arterial carbon dioxide tension difference in the diagnosis of a low cardiac index in patients with septic shock undergoing hyperbaric oxygen therapy for necrotizing fasciitis.",[64,26,65],"Necrotizing Fascitis","Septic Shock",[67,68,69,70,71],"HBO","gapCO2","necrotizing fascitis","cellulitis","cardiac index","2026-05-11",{"date":74,"type":42},"2026-05-14",{"date":76,"type":20},"2026-06-15",{"date":78,"type":20},"2028-03-15",{"name":80,"class":49},"University Hospital, Lille",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":21,"phases":93,"briefSummary":95,"conditions":96,"keywords":100,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":50},"100633919","phase-4-clinical-efficacy-of-stopping-oral-antibiotics-when-symptoms-stop-compared-to-finishing-the-course-100633919","NCT07532941","Clinical Efficacy of Stopping Oral Antibiotics When Symptoms Stop, Compared to 'Finishing the Course'","StopStop@HITH - Clinical Efficacy of Stopping Oral Antibiotics When Symptoms Stop, Compared to 'Finishing the Course', for Children With Bacterial Infections Through Hospital-in-the-Home (HITH): a Basket Randomised Controlled Trial (RCT)","StopStop@HITH","Inclusion Criteria:\n\n1. Between the ages of ≥ 1 years and ≤ 17 years at enrolment\n2. Diagnosis of cellulitis, urinary tract infection (UTI), lower respiratory tract infection (LRTI) or lymphadenitis\n3. Prescription of oral antibiotics as a switch from IV antibiotics\n\nExclusion Criteria:\n\n1. Clinician determined need for \\>10-day oral antibiotic course\n2. Child with immunosuppression (e.g. as a result of cancer treatment)\n3. Second episode of same bacterial infection within the last 28 days\n4. Child is unable to take oral antibiotics\n5. Previous enrolment in StopStop@HITH\n6. Parent\u002Fguardian does not speak English\n7. Clinician determined need for 10-day course of oral antibiotics for treatment\u002Fclearance of streptococcal infection\n8. UTI only: known impaired renal function (e.g. renal transplant patients or known chronic renal failure)\n9. LRTI only: known chronic respiratory condition (e.g. cystic fibrosis or bronchiectasis) or need for long term respiratory support (e.g. home oxygen, Continuous Positive Airway Pressure \\[CPAP\\] or tracheostomy); empyema or lung abscess","1 Year","17 Years",{"count":92,"type":20},200,[94],"PHASE4","The aim of the StopStop@HITH study is to see if stopping antibiotics when symptoms stop is as good as finishing the course of antibiotics. The study will enrol children at the Royal Children's Hospital who are prescribed oral antibiotics after completing a course of intravenous (IV) antibiotics for the treatment of cellulitis, urinary tract infection (UTI), lower respiratory tract infection (LRTI) and lymphadenitis.\n\nThe aims of the study are:\n\n* To determine if oral antibiotics can be safely stopped once symptoms stop in children with cellulitis (who have completed a course of IV antibiotics).\n* To assess feasibility of a larger study of other common infections across multiple hospitals.\n\nThe participants parent\u002Fguardian will complete a daily symptom tracker for the duration of the prescribed oral antibiotic course and attend a telehealth appointment with the study team once the participants symptoms have resolved. There are additional follow up surveys at day 14, day 28 and day 180.",[97,26,98,99],"Urinary Tract Infection","Respiratory Tract Infections","Lymphadenitis",[28,101,102,103],"Antibiotics","Paediatrics","Symptom Guided","2026-04-08",{"date":106,"type":42},"2026-04-16",{"date":108,"type":20},"2026-06",{"date":110,"type":20},"2028-06",{"name":112,"class":49},"Murdoch Childrens Research Institute",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":21,"phases":122,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":141},"100571058","intravenous-versus-oral-treatment-of-the-main-acute-infections-100571058","NCT06715306","Intravenous Versus Oral Treatment of the Main Acute Infections","Intravenous Versus Oral Treatment of the Main Acute Infections in Emergency Departments","Inclusion Criteria:\n\n* Suspected respiratory tract infection, urinary tract infection, or cellulitis by the attending physician\n* Planned or initiated intravenous antibiotic treatment\n\nExclusion Criteria:\n\n* if received more than two doses of intravenous antibiotics;\n* systolic blood pressure \\\u003C90 mmHg;\n* nausea and\u002For vomiting in more than one short-term instance during the last 2 days;\n* suspected significantly reduced gastrointestinal absorption;\n* confirmed plasma-lactate \\> 2;\n* pregnant or nursing;\n* unable to give informed consent;\n* severe immunodeficiency;\n* urgent vital treatment needed.",{"count":121,"type":20},4000,[123],"NA","Patients admitted to the hospital with acute infections are often treated with intravenous (IV) antibiotics. Around 70% of these infections fall into three categories: respiratory tract infections, urinary tract infections, and cellulitis. A Danish study found that 76% of patients admitted with suspected community-acquired pneumonia and treated with antibiotics received them intravenously. Based on an extrapolated estimate from an unpublished local survey, approximately 50,000 patients in Denmark are admitted each year for infections and treated with IV antibiotics. The average hospital stay for these patients is 5.9 days, resulting in a total of 295,000 hospital days annually, accounting for about 7% of total hospital admissions in Denmark. This represents an annual cost of 2.3 billion DKK. While some patients need hospitalization due to their overall health or other serious conditions, others remain hospitalized primarily to receive IV antibiotics.\n\nExpanding the use of oral antibiotics in emergency departments should be pursued only if it can demonstrate comparable efficacy and safety to IV administration. Therefore this study will investigate the efficiency of primarily oral antibiotics in acutely admitted patients with proven or suspected infections. Additionally, the investigators will evaluate the safety of oral regimen for these patients.",[98,126,26],"Urinary Tract Infections",[128,129,130],"Oral antibiotic therapy","intravenous antibiotic therapy","intravenous-to-oral-switch","RECRUITING","2026-03-03",{"date":134,"type":42},"2026-03-05",{"date":136,"type":42},"2025-01-15",{"date":138,"type":20},"2028-01-06",{"name":140,"class":49},"University of Southern Denmark",7,{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":150,"maxAge":90,"enrollmentInfo":151,"targetDuration":4,"studyType":21,"phases":153,"briefSummary":154,"conditions":155,"keywords":160,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":50},"100600150","perspectives-on-antibiotics-and-tracking-symptoms-in-children-100600150","NCT07093749","Perspectives on Antibiotics and Tracking Symptoms in Children","PATSy Perspectives on Antibiotics and Tracking Symptoms in Children - a Mixed Methods Feasibility Study","PATSy","Inclusion Criteria:\n\n* Between the ages of ≥ 4 years and ≤ 17 years at enrolment.\n* Diagnosed with any of the following at RCH ED: urinary tract infection (UTI), cellulitis, impetigo, pharyngitis, tonsillitis, respiratory tract infections, otitis media.\n* Prescribed oral antibiotics (either immediately or as switch from IV antibiotics after transfer to HITH) as standard of care due to having uncomplicated infection as deemed by their treating doctor.\n* Parent\u002Fguardian provides a signed and dated informed consent form.\n\nExclusion Criteria:\n\n\\- Parent\u002Fguardian does not speak English","4 Years",{"count":152,"type":20},300,[123],"The study will assess families' perspectives and decision-making regarding the duration of oral antibiotic courses prescribed to children (4-17 years) who present with uncomplicated bacterial infections at the Royal Children's Hospital (RCH) Emergency Department (ED). The study will involve (i) children discharged from ED on oral antibiotics and (ii) children transferred to Hospital-in-the-Home (HITH) on IV antibiotics who then switch to oral antibiotics. In addition, the study will assess how feasible and acceptable it is to track children's symptoms via the Garmin Smartwatch and the WeGuide platform (WeGuide is a patient engagement software platform that allows for enrolment, consent, and data collection \\[via questionnaires\u002Fsurveys and from the Garmin Smartwatches\\] through a singular platform).",[97,26,156,157,158,98,159],"Impetigo","Pharyngitis","Tonsillitis","Otitis Media",[102,101,161,28],"Digital Health","2025-09-17",{"date":164,"type":42},"2025-09-22",{"date":166,"type":42},"2025-09-16",{"date":168,"type":20},"2026-08",{"name":112,"class":49}]